NCT06382259

Brief Summary

To conduct a randomized crossover trial to determine the acute impact of low-intensity movement breaks on glycemic control in physically inactive individuals living with type 2 diabetes using continuous glucose monitoring.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for not_applicable type-2-diabetes

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 24, 2024

Completed
1 day until next milestone

Study Start

First participant enrolled

April 25, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2025

Completed
Last Updated

May 8, 2024

Status Verified

May 1, 2024

Enrollment Period

1.2 years

First QC Date

April 19, 2024

Last Update Submit

May 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean 24-h glucose concentration assessed using continuous glucose monitoring assessed using continuous glucose monitoring

    The mean 24-h glucose per trial will be determined as the average of the two 24-h periods during that specific trial

    48-hour EX trial versus the 48-hour CON trial

Secondary Outcomes (5)

  • Time in range determined using continuous glucose monitoring

    48-hour EX trial versus the 48-hour CON trial

  • Time above range determined using continuous glucose monitoring

    48-hour EX trial versus the 48-hour CON trial

  • Time below range determined using continuous glucose monitoring

    48-hour EX trial versus the 48-hour CON trial

  • Glycemic variability determined using continuous glucose monitoring

    48-hour EX trial versus the 48-hour CON trial

  • Two-hour glucose area under the curve following standardized breakfast, lunch and dinner meals

    48-hour EX trial versus the 48-hour CON trial

Study Arms (2)

Exercise (EX): Low-intensity movement breaks condition

EXPERIMENTAL

Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.

Other: Movement breaks

Control (CON) Non-exercise control condition

NO INTERVENTION

No structured exercise on two consecutive days.

Interventions

Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.

Exercise (EX): Low-intensity movement breaks condition

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 30-75 years old.
  • Have physician-diagnosed type 2 diabetes.
  • Currently participating in less than 150 minutes of moderate-to-vigorous intensity aerobic exercise per week.
  • Have a body mass index between 18.5 and 40 kg/m2.
  • Have had a stable medication dosage and no changes to the number of prescribed medications for at least 6 months.
  • Able to maintain current medication doses during the study.
  • Able to maintain current physical activity patterns during the study.
  • HbA1c is less than or equal to 8.5%.
  • Have access to a computer, tablet, or smartphone for intervention delivery and tracking.
  • Can travel to McMaster University for in-person laboratory testing visits.
  • Can read, write, and understand English.
  • Anticipate having access to the internet for the duration of the intervention (i.e., over the next 3-4 months).
  • Cleared for exercise participation based on the CSEP Get Active Questionnaire and the Rose Angina Questionnaire.

You may not qualify if:

  • Taking 4 or more glucose-lowering medications.
  • Taking insulin.
  • Taking beta-blockers.
  • Taking 3 or more commonly prescribed medications for the prevention of cardiovascular disease (e.g., statins, antihypertensives).
  • Have had an episode of severe hypoglycemia in the past 6 months (defined as having neurological symptoms consistent with neuroglycopenia and required assistance in treatment by a second party).
  • Currently a cigarette smoker.
  • Have a chronic musculoskeletal condition that would prevent participation in exercise.
  • Have had a recent (within the last 2 years) cardiovascular event that prevents participation in exercise.
  • Experience angina upon exertion.
  • Have uncontrolled high blood pressure (hypertension) or an atypical blood pressure or pulse rate at rest or during exercise as determined by a physician.
  • Have a scheduled surgical procedure within the next 3-4 months that would prevent exercise participation.
  • Currently diagnosed with a cardiac or pulmonary disease (e.g., angina, arrythmia, exercise-induced bronchospasm) that would prevent exercise participation.
  • Have a psychiatric disorder that could prevent you from completing the study procedures or visits.
  • Have donated more than 0.5 L of blood within the last 4 weeks.
  • Currently following an extreme diet (e.g., very low carbohydrate/calorie, ketogenic) or taking dietary/nutritional supplements that impact glucose control (e.g., exogenous ketones).
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of British Columbia Okanagan

Kelowna, British Columbia, V1V 3G1, Canada

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Jonathan Little, PhD

    University of British Columbia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jonathan P Little, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 19, 2024

First Posted

April 24, 2024

Study Start

April 25, 2024

Primary Completion

July 15, 2025

Study Completion

July 15, 2025

Last Updated

May 8, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations